Icosavax announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).
On Mar. 25, 2022, Icosavax announced the first subjects had been dosed with IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain, in a Phase 1/2 clinical trial.
In this topline interim data, IVX-411 was generally safe and well-tolerated. Solicited local and systemic adverse events (AEs) were all mild or moderate, without dose-limiting reactogenicity.
Tags:
Source: Icosavax
Credit:
